InterCure Valuation

Is INCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INCR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INCR's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for INCR?

Key metric: As INCR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for INCR. This is calculated by dividing INCR's market cap by their current revenue.
What is INCR's PS Ratio?
PS Ratio0.8x
Sales₪272.67m
Market Cap₪228.92m

Price to Sales Ratio vs Peers

How does INCR's PS Ratio compare to its peers?

The above table shows the PS ratio for INCR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
NTRB Nutriband
29.6xn/aUS$54.8m
MRMD MariMed
0.4x8.1%US$58.6m
CBST.F Cannabist Company Holdings
0.1x-0.5%US$49.3m
JUSH.F Jushi Holdings
0.2x8.6%US$63.3m
INCR InterCure
0.8xn/aUS$228.9m

Price-To-Sales vs Peers: INCR is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (7.6x).


Price to Sales Ratio vs Industry

How does INCR's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

75 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.6x10.1%
INCR InterCure
0.8xn/aUS$61.76m
OGN Organon
0.6x-0.06%US$3.83b
PRGO Perrigo
0.9x3.4%US$3.69b
INCR 0.8xIndustry Avg. 2.6xNo. of Companies74PS048121620+
75 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.6x23.7%
INCR InterCure
0.8xn/aUS$61.76m
No more companies

Price-To-Sales vs Industry: INCR is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Pharmaceuticals industry average (2.5x).


Price to Sales Ratio vs Fair Ratio

What is INCR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INCR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate INCR's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies